愛康科技(002610.SZ):湖州基地第二條異質結電池產線目前爬坡率80%以上
格隆匯4月19日丨有投資者在投資者互動平台向愛康科技(002610.SZ)提問:你好!貴公司經常報道,參加那麼多場光伏展會,產品還獲得一些光伏專題會的榮譽獎狀,但是就沒看到過報道取得多少訂單,那些國家大型公司的中標榜裏也沒見過貴公司的產品身影。很疑惑,貴公司的異質結產品降本增效做到什麼程度?產銷咋樣?毛利潤有多少?
公司回覆稱,公司2022年的營業收入預計為60~70億元,同比上升137%~177%。具體經營數據請關注公司的定期報吿。公司湖州基地第二條異質結電池產線目前爬產順利,爬坡率已達80%以上,平均轉換效率25.3%,良率已超97%,處於市場領先水平,
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.